Mach7 Technologies (ASX: M7T) is backing itself with a $5 million on-market share buy-back, set to kick off on March 3, 2025, and run for up to 12 months. With a strong cash balance of $25.3 million, the company sees this as an efficient way to manage capital while reaffirming confidence in its future growth.
Backing a Winning Formula
CEO Mike Lampron highlighted that Mach7 has firmly established itself as a serious player in the medical imaging informatics sector, competing with some of the biggest names in the industry. The buy-back is part of a broader capital management strategy that initially focused on reinvesting in growth and innovation. Now, with the company in a strong financial position, the board believes returning value to shareholders is a logical next step.
“We believe the current share price significantly undervalues Mach7,” Lampron said, underlining management’s confidence in the company’s trajectory.
Key Buy-Back Details
- Starts: March 3, 2025
- Value: Up to $5 million
- Duration: Up to 12 months
- Pricing: No more than 5% above the five-day VWAP
- Impact: Shares bought back will be cancelled, reducing total shares on issue
- Manager: Morgans Financial Limited
Future Outlook: Growth Still the Priority
Despite the buy-back, Mach7 is still targeting 15-25% revenue growth for FY25, with operating expenses expected to rise at a slower rate than revenue—a sign of strong financial discipline.
With its next-gen Enterprise Imaging Solution gaining traction in the market, Mach7 is well-positioned to continue expanding its global footprint. The buy-back sends a clear message: Mach7 is confident in its future, and it’s putting its money where its mouth is.
